Universal Ibogaine Inc. (TSXV:IBO)
Canada · Delayed Price · Currency is CAD 0.0050
-0.0050 (-50.00%)
Feb 2, 2026, 9:30 AM EST
Universal Ibogaine Income Statement
Financials in millions CAD. Fiscal year is August - July.
Millions CAD. Fiscal year is Aug - Jul.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 30, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | Jul '20 Jul 31, 2020 |
| 2.06 | 2.33 | 1.03 | 1.07 | - | - | |
Revenue Growth | -11.68% | 126.32% | -3.81% | - | - | - |
Cost of Revenue | 1.7 | 1.78 | 1.06 | 0.57 | - | - |
Gross Profit | 0.36 | 0.55 | -0.03 | 0.5 | - | - |
Selling, General & Admin | 0.62 | 1.04 | 1.61 | 3.66 | 3.8 | 2.34 |
Research & Development | 0.14 | 0.09 | 0.01 | 0.41 | - | 0.02 |
Amortization of Goodwill & Intangibles | - | - | - | - | - | 0.98 |
Operating Expenses | 1.06 | 1.45 | 2.02 | 5.24 | 3.86 | 3.37 |
Operating Income | -0.71 | -0.9 | -2.05 | -4.75 | -3.86 | -3.37 |
Interest Expense | -0.15 | -0.16 | -0.15 | -0.07 | -0.02 | -0.01 |
Currency Exchange Gain (Loss) | - | - | - | - | -0.02 | -0.02 |
Other Non Operating Income (Expenses) | 0.01 | - | -0.01 | -0.13 | 0.03 | -0.06 |
EBT Excluding Unusual Items | -0.85 | -1.06 | -2.22 | -4.94 | -3.87 | -3.45 |
Impairment of Goodwill | - | - | - | -1.46 | - | - |
Gain (Loss) on Sale of Assets | -0.98 | -0.98 | -0.36 | - | - | - |
Asset Writedown | 0.36 | - | - | -1.24 | - | -2.15 |
Other Unusual Items | -0 | -0 | - | -2.85 | - | 0.03 |
Pretax Income | -1.48 | -2.05 | -2.39 | -10.5 | -3.87 | -5.57 |
Net Income | -1.48 | -2.05 | -2.39 | -10.5 | -3.87 | -5.57 |
Net Income to Common | -1.48 | -2.05 | -2.39 | -10.5 | -3.87 | -5.57 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 297 | 233 | 191 | 186 | 125 | 34 |
Shares Outstanding (Diluted) | 297 | 233 | 191 | 186 | 125 | 34 |
Shares Change | 38.51% | 21.54% | 3.05% | 48.28% | 265.15% | 81.31% |
EPS (Basic) | -0.00 | -0.01 | -0.01 | -0.06 | -0.03 | -0.16 |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.06 | -0.03 | -0.16 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 30, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | Jul '20 Jul 31, 2020 |
Free Cash Flow | -0.66 | -0.92 | -1.46 | -4.43 | -3.25 | -2.33 |
Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.02 | -0.03 | -0.07 |
Gross Margin | 17.31% | 23.67% | -2.72% | 46.43% | - | - |
Operating Margin | -34.25% | -38.66% | -199.10% | -443.24% | - | - |
Profit Margin | -71.66% | -88.01% | -232.08% | -980.22% | - | - |
Free Cash Flow Margin | -32.20% | -39.35% | -141.50% | -413.60% | - | - |
EBITDA | -0.36 | -0.56 | -1.75 | -4.48 | -3.8 | -2.36 |
EBITDA Margin | -17.39% | -23.92% | -170.36% | - | - | - |
D&A For EBITDA | 0.35 | 0.34 | 0.3 | 0.27 | 0.07 | 1 |
EBIT | -0.71 | -0.9 | -2.05 | -4.75 | -3.86 | -3.37 |
EBIT Margin | -34.25% | -38.66% | -199.10% | - | - | - |
Advertising Expenses | - | - | - | - | - | 0.31 |